Early Promise for Stem Cell Therapy to Curb MS
Medically reviewed by Drugs.com.
By Dennis Thompson HealthDay Reporter
TUESDAY, Nov. 28, 2023 -- Stem cells injected into the brains of multiple sclerosis patients appear to protect them against further damage from the degenerative disease, a new study shows.
MS occurs when the body’s own immune system attacks and damages the protective sheath around nerve fibers, called myelin. This disrupts messages sent around the brain and spinal cord.
MS patients who received a fetal stem cell injection into their brains did not show any increase in disability or worsening of symptoms during a year-long follow-up period, researchers reported in the Nov. 28 issue of the journal Cell Stem Cell.
“We desperately need to develop new treatments for secondary progressive MS, and I am cautiously very excited about our findings, which are a step towards developing a cell therapy for treating MS,” said co-lead researcher Stephano Pluchino, a professor of regenerative neuroimmunology at the University of Cambridge in the U.K.
More than 2 million people live with MS worldwide, researchers said in background notes. Two-thirds wind up progressing into a debilitating secondary phase of the disease, where their disability grows steadily worse.
But experts said the new study offers hope.
“This was a very small, early-stage study and we need further clinical trials to find out if this treatment has a beneficial effect on the condition. But this is an encouraging step towards a new way of treating some people with MS,” said Caitlin Astbury, research communications manager at the MS Society.
The new study involved 15 highly disabled patients with secondary MS, most of them wheelchair-bound. The patients were recruited from two hospitals in Italy.
Previous mouse studies from the Cambridge team had shown that brain stem cells transplanted into the central nervous system can help reduce damage and potentially might repair damage done by MS.
Researchers injected the patients with brain stem cells taken from a single miscarried fetal donor. The Italian researchers involved in the study have shown the possibility of producing a virtually limitless supply of these stem cells from a single donor.
During the 12-month follow-up period, none of the patients reported symptoms that would suggest a relapse. In addition, none suffered no significant worsening of their cognitive function.
The researchers argue this points to a substantial stabilization of the patients’ disease, although their high levels of disability make it difficult to confirm.
“We recognize that our study has limitations -- it was only a small study and there may have been confounding effects from the immunosuppressant drugs, for example -- but the fact that our treatment was safe and that its effects lasted over the 12 months of the trial means that we can proceed to the next stage of clinical trials,” Pluchino said.
Tests showed that higher doses of stem cells produced higher levels of fatty acids in blood and cerebrospinal fluid, which might be one potential explanation of the protective effects seen in this study, the researchers said.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2023-11-28 20:32
Read more
- First Cases of Sexually Transmitted Ringworm Reported in the U.S.
- Listeria Danger Spurs Nationwide Recall of Frozen Waffles
- The Right Time is Now to Get Your Flu Vaccine
- FDA Approves Itovebi for Locally Advanced, Metastatic Breast Cancer
- NIH Clinical Trial Will Test Precision Medicine Treatments for Myeloid Cancers
- Burger King, Other Fast Food Chains Also Pulling Onions Tied to E. Coli Outbreak
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions